| A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine (NCT00516802) | AstraZeneca | 2007-01-01 |
| Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma (NCT00423332) | AstraZeneca | 2007-01-01 |
| Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide (NCT00608153) | AstraZeneca | 2007-01-01 |
| Evaluation of Crestor® (Rosuvastatin) in Daily Practice (NCT00837083) | AstraZeneca | 2007-01-01 |
| An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma (NCT00419757) | AstraZeneca | 2007-01-01 |
| Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH (NCT00607633) | AstraZeneca | 2007-01-01 |
| A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD (NCT00419744) | AstraZeneca | 2007-01-01 |
| Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128) (NCT00424268) | AstraZeneca | 2007-01-01 |
| Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo (NCT00434967) | AstraZeneca | 2007-01-01 |
| SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients (NCT00608868) | AstraZeneca | 2007-01-01 |
| Electronic Health Record (EHR)-Based Intervention for Gastroesophageal Reflux Disease (GERD) and Chronic Non-steroidal Anti-inflammatory Drug (NSAID) Use (NCT00691171) | AstraZeneca | 2007-01-01 |
| Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic Patients (NCT00473655) | AstraZeneca | 2007-01-01 |
| Study to Assess Safety of AZD7762 Administered Alone and in Combination With Gemcitabine in Patients With Advanced Solid Malignancies (NCT00413686) | AstraZeneca | 2006-12-01 |
| Study of Efficacy and Safety of Seroquel (Quetiapine Fumarate) as Mono-Therapy for Acute Schizophrenic (NCT00428350) | AstraZeneca | 2006-12-01 |
| Study of Asian Patients With Hypercholesterolaemia in the UK - Rosuvastatin 5mg Versus Atorvastatin 10mg (NCT00427960) | AstraZeneca | 2006-12-01 |
| Safety and Efficacy Study of Budesonide (Pulmicort®) Turbuhaler® in Japanese Children With Bronchial Asthma (NCT00509028) | AstraZeneca | 2006-12-01 |
| Phase III/Seroquel SR Bipolar Depression Monotherapy - US (NCT00422214) | AstraZeneca | 2006-12-01 |
| Non-interventional Study to Evaluate Arimidex in Postmenopausal Women With Advanced Breast Cancer (NCT00562458) | AstraZeneca | 2006-12-01 |
| Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients (NCT00394472) | AstraZeneca | 2006-11-01 |
| A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects (NCT00402077) | AstraZeneca | 2006-11-01 |
| Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma (NCT00372853) | AstraZeneca | 2006-11-01 |
| Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490) (NCT00806754) | AstraZeneca | 2006-11-01 |
| Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer (NCT00399035) | AstraZeneca | 2006-11-01 |
| Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102) (NCT00404547) | AstraZeneca | 2006-11-01 |
| A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome (NCT00391872) | AstraZeneca | 2006-10-01 |
| A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-413) (NCT00384475) | AstraZeneca | 2006-10-01 |
| Efficacy and Safety of Esomeprazole Once Daily for the Treatment of GERD in Neonatal Patients (NCT00427635) | AstraZeneca | 2006-10-01 |
| A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects (NCT00392925) | AstraZeneca | 2006-10-01 |
| Asthma Patient Survey Study to Assess Asthma Effect and Medication in Finland (NCT00681382) | AstraZeneca | 2006-10-01 |
| Pulmicort Respules 0.25/0.5 Specific Clinical Experience Investigation (NCT01232322) | AstraZeneca | 2006-10-01 |
| Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD (NCT00410592) | AstraZeneca | 2006-10-01 |
| Efficacy and Safety Study of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease (NCT00573469) | AstraZeneca | 2006-10-01 |
| Patient's Anastrozole Compliance to Therapy Programme (NCT00555867) | AstraZeneca | 2006-10-01 |
| Open-label, Safety and Efficacy Study of Pulmicort® Turbuhaler® in Japanese Children With Bronchial Asthma (NCT00504062) | AstraZeneca | 2006-10-01 |
| An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium (NCT00428701) | AstraZeneca | 2006-10-01 |
| Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone (NCT00391846) | AstraZeneca | 2006-10-01 |
| A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes (NCT00357370) | AstraZeneca | 2006-10-01 |
| Effect on Weight Loss of Exenatide Versus Placebo (NCT00375492) | AstraZeneca | 2006-09-01 |
| A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes (NCT00382239) | AstraZeneca | 2006-09-01 |
| Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors (NCT00389389) | AstraZeneca | 2006-09-01 |
| Exenatide Versus Glimepiride in Patients With Type 2 Diabetes (NCT00359762) | AstraZeneca | 2006-09-01 |
| Phase II Efficacy Study of AZD6244 in Colorectal Cancer (NCT00514761) | AstraZeneca | 2006-09-01 |
| Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD (NCT00421122) | AstraZeneca | 2006-09-01 |
| A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise (NCT00374907) | AstraZeneca | 2006-09-01 |
| Airway Clearance Study (NCT00379028) | AstraZeneca | 2006-09-01 |
| Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg (NCT00383929) | AstraZeneca | 2006-09-01 |
| Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 Diabetes (NCT00359879) | AstraZeneca | 2006-09-01 |
| Safety and Efficacy of Exenatide as Monotherapy (NCT00381342) | AstraZeneca | 2006-09-01 |
| ROMEO (Rosuvastatin in Metabolic syndrOme) (NCT00395486) | AstraZeneca | 2006-09-01 |
| Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder (NCT00388973) | AstraZeneca | 2006-09-01 |
| A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With Asthma (NCT00384189) | AstraZeneca | 2006-09-01 |
| Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder (NCT00389064) | AstraZeneca | 2006-09-01 |
| Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma. (NCT00392288) | AstraZeneca | 2006-09-01 |
| The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST). (NCT00385203) | AstraZeneca | 2006-09-01 |
| Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults (NCT00385593) | AstraZeneca | 2006-09-01 |
| Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler (NCT00812682) | AstraZeneca | 2006-09-01 |
| PPI Sequencing Study (NCT00384592) | AstraZeneca | 2006-09-01 |
| First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX (NCT00384176) | AstraZeneca | 2006-08-30 |
| Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD) (NCT00358436) | AstraZeneca | 2006-08-01 |
| Pharmacokinetic Study of Esomeprazole Magnesium in Patients 1 to 11 Years-Old With Endoscopically-Proven Gastroesophageal Reflux Disease (GERD) (NCT00687245) | AstraZeneca | 2006-08-01 |
| Efficacy of 500µg Roflumilast Once Daily Versus Placebo Over 12 Weeks in Patients With Diabetes Mellitus Type 2. A Double Blind, Parallel Group, Proof of Concept Clinical Study (NCT01140542) | AstraZeneca | 2006-08-01 |
| AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen (NCT00372788) | AstraZeneca | 2006-08-01 |
| AZD1152 in Patients With Advanced Solid Malignancies-Study 3 (NCT00497679) | AstraZeneca | 2006-08-01 |
| AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy (NCT00372944) | AstraZeneca | 2006-08-01 |
| Efficacy and Safety Study of Esomeprazole vs Omeprazole to Treat Acute Non-Variceal Upper Gastrointestinal Bleeding (NCT00402259) | AstraZeneca | 2006-08-01 |
| Symptom Adapted Therapy in GERD Patients (NCT00343161) | AstraZeneca | 2006-08-01 |
| PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin (NCT00355615) | AstraZeneca | 2006-07-01 |
| Randomised Study to Compare the Efficacy of AZD6244 vs TMZ (NCT00338130) | AstraZeneca | 2006-07-01 |
| A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD) (NCT00363896) | AstraZeneca | 2006-07-01 |
| A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients (NCT00360334) | AstraZeneca | 2006-06-01 |
| Impact of GERD on Daily Life (NIS) (NCT00545883) | AstraZeneca | 2006-06-01 |
| Effect of Food Upon Pharmacokinetics of Single Oral Dose of Cediranib (AZD2171, Recentin™) (NCT00306891) | AstraZeneca | 2006-06-01 |
| Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP) (NCT00348686) | AstraZeneca | 2006-06-01 |
| Arthralgia During Anastrozole Therapy for Breast Cancer (NCT00323479) | AstraZeneca | 2006-06-01 |
| Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise (NCT00316082) | AstraZeneca | 2006-06-01 |
| Efficacy of Quetiapine in Generalised Social Anxiety Disorder (NCT00302770) | AstraZeneca | 2006-06-01 |
| Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody (NCT00431275) | AstraZeneca | 2006-06-01 |
| A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg (NCT00313170) | AstraZeneca | 2006-05-30 |
| AZD1152 in Patients With Advanced Solid Malignancies (NCT00338182) | AstraZeneca | 2006-05-23 |
| Responsiveness of Lower Airways in Adult Patients (18-60 Years) With Stable Asthma After Treatment With Ciclesonide and Fluticasone Propionate (BY9010/NL-101) (NCT00306163) | AstraZeneca | 2006-05-01 |
| Seroquel (Quetiapine Fumarate) InPractice Evaluation Programme (NCT00921362) | AstraZeneca | 2006-05-01 |
| Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia (NCT00497991) | AstraZeneca | 2006-05-01 |
| Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder (NCT00351910) | AstraZeneca | 2006-05-01 |
| Nexium RESPONSE Trial (NCT00318968) | AstraZeneca | 2006-05-01 |
| Efficacy and Safety Study of Seroquel SR in the Treatment of Generalized Anxiety Disorder (NCT00322595) | AstraZeneca | 2006-05-01 |
| Prevention of Asthma Relapse After Discharge From Emergency (NCT00326053) | AstraZeneca | 2006-05-01 |
| Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder (NCT00351169) | AstraZeneca | 2006-05-01 |
| A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise (NCT00327015) | AstraZeneca | 2006-05-01 |
| Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC) (NCT00312975) | AstraZeneca | 2006-05-01 |
| Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment (NCT00313794) | AstraZeneca | 2006-05-01 |
| A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas (NCT00313313) | AstraZeneca | 2006-04-01 |
| A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus (NCT00313183) | AstraZeneca | 2006-04-01 |
| Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1) (NCT00308139) | AstraZeneca | 2006-04-01 |
| Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127) (NCT00313209) | AstraZeneca | 2006-04-01 |
| Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive Disorders (NCT00326105) | AstraZeneca | 2006-04-01 |
| Ropivacaine Versus Bupivacaine for Spinal Anaesthesia in Patients Undergoing Unilateral Lower Limb Surgery (NCT00358280) | AstraZeneca | 2006-04-01 |
| Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Major Depressive Disorder (NCT00320268) | AstraZeneca | 2006-04-01 |
| Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer (NCT00357110) | AstraZeneca | 2006-04-01 |
| Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Generalized Anxiety Disorder (NCT00329264) | AstraZeneca | 2006-04-01 |
| Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder (NCT00329446) | AstraZeneca | 2006-04-01 |